secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001818331-26-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M
--------------------------------------------------------------------------------

- Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).
- Q4 exome/genome volume 27,761 (+34.3% YoY); adjusted gross margin 71%.
- FY2025 revenue $427.5M (+41%); adjusted net income $41.8M vs $9.4M prior year.
- Reaffirmed FY2026 revenue guidance $540-555M with 33-35% exome/genome volume growth.
- Cash $172.3M; Q4 operating cash flow $5.1M; issued 147,583 shares via ATM netting $21.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833126000014/0001818331-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833126000014/wgs-20260223.htm
  HTML page:      https://secwatch.observer/filing/0001818331-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer